Merck continues to perform pretty well in the last quarter and delivered another all-around beat while continuing to bid on long-term growth. During the quarter, it achieved robust bottom and top-line growth and has made some additional vital clinical advancements in its pipelines. The exceptional performance in the quarter was led by robust growth of main products, which include Bridion, Gardasil, and Keytruda. For pediatric cases, Vaxneuvance has received an extended approval from the FDA. The ....
29 Aug 2022
Merck Inc.: Keytruda & Other Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (08/22)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Merck Inc.: Keytruda & Other Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (08/22)
- Published:
29 Aug 2022 -
Author:
Ishan Majumdar -
Pages:
27
Merck continues to perform pretty well in the last quarter and delivered another all-around beat while continuing to bid on long-term growth. During the quarter, it achieved robust bottom and top-line growth and has made some additional vital clinical advancements in its pipelines. The exceptional performance in the quarter was led by robust growth of main products, which include Bridion, Gardasil, and Keytruda. For pediatric cases, Vaxneuvance has received an extended approval from the FDA. The ....